The clinical research of late course hyperfractionated radiotherapy plus different chemotherapy for esophageal carcinoma
10.3760/cma.j.issn.1673-422X.2009.03.025
- VernacularTitle:后程超分割放疗协同不同化疗方案治疗食管癌的临床研究
- Author:
Guangming ZHANG
;
Wenkui MAO
;
Huilan LONG
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Radiotherapy;
Drug therapy;
Dosage fractionation;
Prognosis
- From:
Journal of International Oncology
2009;36(3):236-239
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the treatment results and side-reactions of esophageal carcinoma with late course hyperfractionated radiotherapy ( LCHR) plus different chemotherapy. Methods A prospective research was carried out on 287 advanced stage esophageal carcinoma patients whom were randomized into there groups;LCHR + cisplatin +5-fluorouracil +leucovorin group( A group), LCHR +5-fluorouracil polyphase lipo- some group (B group) and LCHR group(C group). 115 patients were in A group and 107 patients in B group and 65 patients in C group. Radiotherapy method; there groups were treated by conventional fractionated radio- therapy during the first two-thirds of the whole course with 40 Cy,then followed by isocenter hyperfractionated radiotherapy to keep away of spinal marrow, 1. 3-1. 5Gy per time,2 times a day and 5 days a week. The total dose was 60-66 Gy in A, B group and 60-70 Gy in C group. The preventive dose was 50 Gy. Results There was no statistically difference among the there groups on the short-term curative effect The 1- ,2- ,3-year local control rate was 80% ,50.4% ,42.6% and 72.9% ,51.4% ,41. 1% and 63.1% ,38.5% ,30.8%
